N/A
Completed N=10
Ketone Production With Acute Caffeine Intake
Healthy Adults
Source: ClinicalTrials.gov NCT02694601 ↗
Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Jun 2018
Primary outcomePrimary: Plasma Acetoacetate Concentrations — 26.06; 30.99; 32.10 µmol/L
Summary
Evaluate the effect of a caffeine supplement on the stimulation of lipolysis and the production of ketones in healthy adults (N=10).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Plasma Acetoacetate Concentrations |
26.06; 30.99; 32.10 | — |
| PRIMARY Plasma Beta-hydroxybutyrate Concentrations |
92.69; 127.57; 144.99 | — |
| SECONDARY Plasma Glucose Concentrations |
4.95; 4.96; 4.98 | — |
| SECONDARY Plasma Cholesterol Concentrations |
4.26; 4.76; 4.81 | — |
| SECONDARY Plasma Triglyceride Concentrations |
0.90; 0.92; 0.97 | — |
Eligibility Criteria
Inclusion Criteria
- Healthy adults
- 18 years old and over
Exclusion Criteria
- Drinking more than 300 mg of caffeine per day
- Diabetes or prediabetes
- Abnormal liver and kidney function
- Uncontrolled dyslipidemia, blood pressure
- Use of drugs known to influence the metabolism of lipids and carbohydrates (steroid, beta-blockers, diuretics, insulin sensitizer, etc.)
- Severe inflammation or infection
- Pregnancy
- Smoking
Data sourced from ClinicalTrials.gov (NCT02694601). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.